The registered shares of Actelion Ltd were second listed on the SWX New Market on April 6, 2000 (symbol: ATLN). A total of 1,000,000 primary shares were placed at the company’s Initial Public Offering (IPO), at a price of CHF 260 per share, raising CHF 246.6 million.
On 8 July 2008, the Management Committee of the SIX Swiss Exchange decided to add Actelion shares (ATLN, CH0010532478) to the Swiss Market Index SMI®. Actelion shares have traded as part of the SMI since 22nd September 2008.
In November 2010, Actelion commenced the repurchase of up to CHF 800 million of the company’s common stock over the next three years via a second trading line on the SIX Swiss exchange. At subsequent Annual General Meetings, the Board of Directors will propose that the shares bought through this process be cancelled and the issued share capital reduced accordingly.
On 7 December 2011, Actelion Ltd raised CHF 235 million through a 4 year, 4.875% Swiss Franc bond.
Issue price was 100.25%. The bonds will mature on 7 December 2015 at par. The coupon of the bonds is subject to Swiss withholding tax of 35%.
Actelion Ltd is part of the following indices: SMI, SPI, SLI, SPIMLC, SPI20, SPISMC, SXXP, SXDP, SBC100, SNSPIX, SMHCAX, SLDI, SXI LIFE SCIENCES and SXI Bio+Medtech.
Actelion is traded under the following symbols: Reuters: ATLN.S/ Bloomberg ATLN.
Key share data
|As of 31.03.2013|
|Shares outstanding as of 31.03.2013||126.7 million|
|Closing share price as of 31.03.2013||CHF 51.55|
|Market capitalization as of31.03.2013||CHF 6.5 billion|
|52-week high||CHF 51.85|
|52-week low||CHF 31.88|
|YTD price change||+17 %|
|Average daily volume||0.4 million|
|Free float||89.9 %|
|As of 31.03.2013|
|Number of registered shareholders||10,565|
As of 31.03.2013
|Actelion Ltd||> 5 %|
|Management and Directors||> 5 %|
|Orbis||> 5 %|
|BB Biotech||> 3 %|
|Blackrock||> 3 %|
|Rudolf Maag||> 3 %|
|Lazard Asset Mgmt||> 3 %|
This content is updated on a quarterly basis.